BIOCHEMICAL OBSERVATIONS
Cerebrospinal fluid (CSF) GABA content is reduced in epilepsy (Wood et al. 1979; Manyam et al. 1980) . A preliminary report found normal GABA levels in untreated schizophrenic patients and reduced levels following neuroleptic therapy (Lichtshtein et al. 1978) , but the methodology employed has been questioned . Gold et al. (1980) also found no difference between controls and schizophrenic patients. However, a recent report (McCarthy et al. 1981) described an increased CSF GABA content in patients with chronic schizophrenia.
Glutamic acid decarboxylase (GAD), the enzyme synthesizing GABA, was reported to be reduced in activity in the putamen, nucleus accumbens, amygdala and hippocampus of patients with chronic schizophrenia (Bird et al. 1977) . This change was subsequently found to be largely or entirely dependent on the mode of death, a prolonged ante-mortem period of cerebral hypoxia, as in death from bronchopneumonia, being associated with a fall in GAD activity in deep brain nuclei (Bowen et al. 1976; McGeer & McGeer, 1979; Bird et al. 1979) . Differences in GAD activity in the striatum, nucleus accumbens, or hippocampus are not found in a comparison of controls and schizophrenics who have died suddenly (Bird et al. 1979) .
The mean brain GABA content of the nucleus accumbens and of the thalamus was originally reported to be reduced in brains from chronic schizophrenic patients (Perry et al. 1979) . A subsequent report found no difference in GABA concentration in the nucleus accumbens and thalamus compared with controls. A larger and more recent study finds small but significant decreases in GABA concentration in the nucleus accumbens and in the amygdala (Spokes et al. 1980) . In summary, available biochemical studies neither provide definitive evidence for the hypothesis of GABAergic deficiency in schizophrenia, nor do they disprove it.
PHARMACOLOGICAL STUDIES
Clinical pharmacological studies are all concerned with drugs which either directly mimic the action of GABA or enhance the action of endogenous GABA, since drugs which impair the inhibitory action of GABA are convulsant.
GABA agonists act at GABA receptor sites to reproduce the physiological actions of GABA. Thus there are at least as many different types of GABA agonist as there are types of GABA receptor. The latter can be defined by anatomical, physiological, pharmacological or biochemical procedures (Meldrum et al. 1980; Meldrum, 1981) .
The classical physiological test system concerns post-synaptic inhibition (in the neocortex, cerebellum, hippocampus or spinal cord) which is bicuculline-sensitive and strychnine-insensitive, assessed at the single cell level with microelectrodes (Curtis, 1979) . In this test system muscimol and various new synthetic compounds are potent GABA agonists; baclofen, 4-hydroxybutyrate and valproate are relatively inactive. There are also four or more different 'pre-synaptic' sites at which GABA may act to modify neurotransmission (Meldrum, 1981) . Among these, the inhibition of primary afferent transmission in the spinal cord is the best studied. Pharmacologically, it is similar to GABA-mediated post-synaptic inhibition. There are also GABA sensitive 'autoreceptors' on GABAergic terminals (Mitchell & Martin, 1978) ; 5-amino-laevulinic acid is a potent agonist at this site (Brennan & Cantrill, 1979) . In the peripheral autonomic nervous system and in the brain the release of monoamines can be inhibited by GABA and by baclofen (Bowery et al. 1980) , through an action on a pre-synaptic receptor that is not bicuculline-sensitive. There is evidence for GABAsensitive pre-synaptic receptors which influence the release of glutamate and aspartate (Gallo et al. 1981; Collins, 1980) , but their pharmacology remains to be defined. There are also GABA receptors on axonal membranes which have been studied, using dorsal nerve root or cervical sympathetic ganglion preparations (Bowery & Brown, 1974; Brown & Marsh, 1978) .
The physiological role of post-synaptic inhibition and of primary afferent pre-synaptic inhibition is partially understood, but the functional significance of other GABA receptors in the brain is totally obscure. The principal method for the study of their possible roles is the focal injection of GABA or GABA agonists in animal behavioural models. In certain such tests baclofen and 4-hydroxybutyrate, like muscimol, reproduce the effect of focal GABA injection (Olpe et al. 1977) . In man, GABA agonists and GABA-mimetics have been administered orally in a variety of experimental studies (see Table 1 ). Some of these studies were performed in patients with schizophrenia in the hope of identifying a therapeutic action either against acute psychotic symptoms (Tamminga et al. 1978; Lautin et al. 1980) or against the syndrome of tardive dyskinesia (Tamminga et al. 1979; Casey et al. 1980) . As muscimol was known to be capable of inducing toxic psychosis in the normal volunteer (Waser, 1967) , the exacerbation in psychosis scores found in schizophrenic patients was not unexpected. This exacerbation has been widely assumed to be a toxic side-effect of muscimol, not specifically related to its GABA agonist action. However, this effect should probably be considered in relation to the evidence for a worsening of psychotic symptoms in the majority of patients with acute or chronic schizophrenia treated with baclofen or with sodium valproate (Simpson et al. 1976; Davis et al. 1976; Lautin et al. 1980) . In addition, several trials of these GABAmimetics and of GABA-transaminase inhibitors which enhance brain GABA content (Meldrum, 1979; Palfreyman et al. 1981 ) in Huntington's disease or Parkinson's disease report the induction of an acute psychosis in a minority of patients (see Table 1 ).
A tentative interpretation of these clinical observations is that endogenous GABA in excess, true GABA agonists such as muscimol, or GABA-mimetics can all produce an acute psychosis by acting at a GABA receptor which has many of the features reported in studies of pre-synaptic GABA receptors. Interestingly, #-amino-laevulinic acid, a potent, pre-synaptic GABA agonist, accumulates in porphyria. Loading with serine or glycine, the metabolic precursor of <J-amino-laevulinic acid, can precipitate a schizophrenia-like psychosis in patients with porphyria or related illnesses (Pepplinkuizen et al. 1980) . The concentration of 5-amino-laevulinic acid in the CSF during an attack of acute intermittent porphyria (Sweeney et al. 1970 ) is equivalent to that producing a 50 % inhibition of GABA release from synaptosomes through an autoreceptor effect (Brennan & Cantrill, 1979) .
Among the clinical studies summarized in Table 1 only those concerning muscimol in schizophrenic patients (Tamminga et al. 1978 (Tamminga et al. , 1979 employed quantitative measures of specific schizophrenic symptoms. The majority of the cases reported conform to the pattern of acute toxic psychosis.
In summary, clinical studies with GABA agonists or GABA-mimetics show no therapeutic action against the positive symptoms of acute schizophrenia, and thus provide no support for a GABAdeficiency hypothesis of schizophrenia. By contrast, high doses of drugs known to act at GABA receptors other than the receptor responsible for post-synaptic inhibition are all capable of inducing acute psychoses, which vary from an apparent exacerbation of the schizophrenic syndrome in patients with acute schizophrenia to an organic confusional state in patients with a variety of neurological disorders. Thus an excessive local release of GABA, or hypersensitivity of a subgroup of GABA receptors, or an endogenous GABA agonist (such as (S-amino-laevulinic acid) might be responsible for some features of acute psychotic syndromes. BRIAN MELDRUM 
